ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Surescripts Touchless Prior Authorization Surpasses 76,000 Prescribers, Ushering in a New Era of Medication Access

Surescripts®, the nation's leading health intelligence network, today announced a major expansion of its Touchless Prior Authorization technology, now reaching more than 76,000 prescribers across the country. Since launching earlier this year, the product has grown to support more than 70 medications—and that number continues to rise as additional therapies are added. This milestone marks a transformative shift in how prior authorizations for medications are handled—automating a historically manual process to accelerate time to therapy and minimize treatment delays.

Touchless Prior Authorization is live across leading health systems, including:

  • Cleveland Clinic
  • Fairview Health Services
  • Garnet Health
  • The Ohio State University Medical Center
  • UNC Health
  • Watson Clinic

“Momentum is building across the industry,” said Frank Harvey, Chief Executive Officer for Surescripts. “Since launching this year, and with tens of thousands of prescribers already on board, Touchless Prior Authorization is proving that we can eliminate the friction in medication access and deliver real-time, high-quality care at scale.”

Prior authorization is meant to protect patient safety and support cost-effective care, but manual processes often delay treatment and frustrate patients and providers alike. Touchless Prior Authorization automates the process by pulling clinical data from the electronic health record and sending it to the pharmacy benefit manager allowing approvals to happen quickly and patients to start medication sooner, with less work for everyone.

“This is more than automation—it’s transformation,” said Tara Dragert, Chief Product Officer for Surescripts. “Touchless Prior Authorization has already grown to support more than 70 medications since its launch, and we’re continuing to expand its reach to additional therapies. This technology ensures patients can quickly access the safe, quality care they need and deserve, while significantly reducing barriers to treatment.”

Health systems and the results speak for themselves:

  • 22 seconds median approval time for in-scope medications1
  • 88% fewer appeals during pilot programs2
  • 68% fewer denials due to missing information3

“The traditional prior authorization process can be slow, difficult to manage, and often leads to treatment delays,” said Christine Carmichael, Financial Access Service Manager for Fairview Health Services. “Every delay adds stress for patients and frustration for providers. We’ve implemented technology-driven improvements to streamline prior authorizations and allow clinicians to focus on what matters most delivering care.”

“When prior authorization takes time to complete, it can lead to delays in treatments and creates frustration for providers and patients alike,” said Angela Odham, System Executive Director for UNC Health. “We saw an opportunity to change that and became an early adopter of Touchless Prior Authorization, which has helped our patients start treatment faster and allowed clinicians to focus on care.”

"Trading the historically burdensome prior authorization process for a fast and seamless experience that is centered on patient care was an easy decision," said Dr. Joseph Chavez Carey, Medical Director for Primary Care at Garnet Health Doctors. “Touchless Prior Authorization is a clear example of how smart technology can drive meaningful change in healthcare delivery.”

Manual prior authorization processes still dominate across much of the industry. In a recent survey, more than half of prescribers said prior authorization delays or denials for prescriptions are a major challenge in their day-to-day work. One in five selected a task related to prescription prior authorizations as the biggest daily challenge they face.

Learn more about how Touchless Prior Authorization is transforming care at Surescripts at HLTH 2025 – October 19–22, Las Vegas, NV.

Stop by Booth #2318 to explore how we’re collaborating across healthcare, bringing innovative technology to care providers, delivering real-time insights and automating processes to help keep patient care on track.

About Surescripts

Our purpose is to serve the nation through simpler, trusted health intelligence sharing, in order to increase patient safety, lower costs and ensure quality care. At Surescripts, we bring healthcare together to inform and accelerate decisions, helping keep patient care on track. With the Surescripts Network Alliance®, we’re empowering the healthcare ecosystem with intelligence and interoperability for smarter, faster prescribing, prior authorization, treatment, care management and more. Visit us at surescripts.com and follow us on LinkedIn.

1 Surescripts network data, January 2025 through October 2025.

2 KLAS Research K2 Collaborative, "Case Study: Leveraging Innovative Technology to Streamline Medication Prior Authorizations," September 2024, p. 3.

3 KLAS Research K2 Collaborative, "Case Study: Leveraging Innovative Technology to Streamline Medication Prior Authorizations,” p. 3.

“With tens of thousands of prescribers already on board, Touchless Prior Authorization is proving that we can eliminate the friction in medication access and deliver real-time, high-quality care at scale,” said Frank Harvey, CEO for Surescripts.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.16
-0.51 (-0.22%)
AAPL  277.55
+0.58 (0.21%)
AMD  214.24
+8.11 (3.93%)
BAC  52.99
+0.51 (0.97%)
GOOG  320.28
-3.36 (-1.04%)
META  633.61
-2.61 (-0.41%)
MSFT  485.50
+8.51 (1.78%)
NVDA  180.26
+2.44 (1.37%)
ORCL  204.96
+7.93 (4.02%)
TSLA  426.58
+7.18 (1.71%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.